Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Tino

Physician Assistant Manchester, CT Physician Assistant

NPI 1447533534 CMS profile 10734464

353 Main St, Manchester, CT 06040

Open in the dashboard

General payments

$11,162

553 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Tino of Manchester, CT is reported in the CMS Open Payments database as having received $11,162 across 553 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,159 99
2024 General $2,158 103
2023 General $2,439 121
2022 General $2,351 120
2021 General $2,056 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Tino
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nicole Tino were reported at $2,159. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nicole Tino Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,056 $132 $37–$438 $132
2022 $2,351 $155 $48–$522 $149
2023 $2,439 $167 $52–$557 $160
2024 $2,158 $178 $55–$600 $164
2025 $2,159 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,342 131 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,796 97 payments
  3. Gilead Sciences, Inc. $974 50 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $810 32 payments
  5. Celgene Corporation $745 42 payments
  6. QOL Medical, LLC $662 23 payments
  7. Ardelyx, Inc. $549 25 payments
  8. Janssen Biotech, Inc. $439 20 payments
  9. Intercept Pharmaceuticals, Inc. $334 16 payments
  10. Regeneron Healthcare Solutions, Inc. $281 11 payments
  11. Other $2,232 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,041 550 payments
  2. Long term medical supply or device loan $82 1 payment
  3. Education $39 2 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,390 63 payments
  2. ZEPOSIA $802 41 payments
  3. RINVOQ $786 44 payments
  4. SKYRIZI $742 39 payments
  5. IBSRELA $549 25 payments
  6. ENTYVIO $468 18 payments
  7. CREON $466 27 payments
  8. LINZESS $449 27 payments
  9. TRULANCE $405 34 payments
  10. STELARA $340 15 payments
  11. Other $5,683 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

984

Median for Physician Assistant: 241

Drug cost

$227,556

Median for Physician Assistant: $4,110

Branded share of claims

36%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 38 $99,370
Linzess Linaclotide Brand 104 $78,370
Trulance Plecanatide Brand 36 $25,382
Dexlansoprazole Dr Dexlansoprazole Brand 33 $8,749
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 91 $5,231
Pantoprazole Sodium Generic 247 $2,811
Omeprazole Generic 135 $2,215
Famotidine Generic 101 $1,826
Esomeprazole Magnesium Generic 50 $754
Lansoprazole Generic 31 $673

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$32,681

Medicare's payments for the services billed

Medicare patients

256

Average age 75

Services billed

470

165 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Ischemic heart disease 29%
Depression 29%
Atrial fibrillation 28%
Chronic kidney disease 27%
Diabetes 21%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $293
$293 — —
SKYRIZI
  • AbbVie, Inc. $231
$231 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $208
$208 — —
RINVOQ
  • AbbVie, Inc. $191
$191 — —
IBSRELA
  • Ardelyx, Inc. $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

553 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record